Amide compounds are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds as well as methods of treating neurodegenerative diseases that involve administering the compounds or pharmaceutical compositions to a subject.

Amide compounds are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds as well as methods of treating neurodegenerative diseases that involve administering the compounds or pharmaceutical compositions to a subject.

Disclosed are a sulfonic acid-modified polyisocyanate and a preparation method thereof. By controlling a content of cyclohexylamine component in the raw material, the reaction rate of sulfamic acid and polyisocyanate is accelerated, so that the prepared product has advantages of light color and low turbidity as well as good storage stability.

Disclosed are a sulfonic acid-modified polyisocyanate and a preparation method thereof. By controlling a content of cyclohexylamine component in the raw material, the reaction rate of sulfamic acid and polyisocyanate is accelerated, so that the prepared product has advantages of light color and low turbidity as well as good storage stability.

The present invention relates to a crystalline form of compound 3-((L-valyl)amino)-3,3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof.

The present invention relates to a crystalline form of compound 3-((L-valyl)amino)-3,3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof.

The present invention relates to a crystalline form of compound 3-((L-valyl)amino)-3,3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof.

A process for enhanced oil recovery comprising the following steps: a) Preparation of an injection fluid comprising at least one water-soluble (co)polymer prepared at least from 2-acrylamido-2-methylpropane sulfonic acid (ATBS) or from at least one of its salts, with water or with brine, where the 2-acrylamido-2-methylpropane sulfonic acid is a hydrated crystalline form of 2-acrylamido-2-methylpropane sulfonic acid having a 2-theta powder X-ray diffraction diagram comprising peaks at 10.58°, 11.2°, 12.65°, 13.66°, 16.28°, 18.45°, 20°, 20.4°, 22.5°, 25.5°, 25.88°, 26.47°, 28.52°, 30.28°, 30.8°, 34.09°, 38.19°, 40.69°, 41.82°, 43.74°, 46.04° degrees. b) Injection of injection fluid into an underground formation, c) Flushing of the underground formation using the fluid injected, d) Recovery of an aqueous and hydrocarbon mixture.

A process for enhanced oil recovery comprising the following steps: a) Preparation of an injection fluid comprising at least one water-soluble (co)polymer prepared at least from 2-acrylamido-2-methylpropane sulfonic acid (ATBS) or from at least one of its salts, with water or with brine, where the 2-acrylamido-2-methylpropane sulfonic acid is a hydrated crystalline form of 2-acrylamido-2-methylpropane sulfonic acid having a 2-theta powder X-ray diffraction diagram comprising peaks at 10.58°, 11.2°, 12.65°, 13.66°, 16.28°, 18.45°, 20°, 20.4°, 22.5°, 25.5°, 25.88°, 26.47°, 28.52°, 30.28°, 30.8°, 34.09°, 38.19°, 40.69°, 41.82°, 43.74°, 46.04° degrees. b) Injection of injection fluid into an underground formation, c) Flushing of the underground formation using the fluid injected, d) Recovery of an aqueous and hydrocarbon mixture.

There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment of amyloid-β related diseases, such as Alzheimer's disease.

R.sup.1R.sup.2X—CR.sub.2—CH.sub.2—CH.sub.2—SO.sub.3H   (I)